London HIV Consortium Issues New Guidelines for ARV Prescribing
The London HIV Consortium, the pan-London commissioning group for HIV services, has just outlined the results of the tender process for purchasing HIV drugs for the next two years. This is part of an ongoing process to manage the HIV budget within government-imposed restrictions on NHS budgets. Over two years the group is faced with having to make savings of approximately £10 million to mange the same service on a budget that has not increased in line with inflation.
This will change the way that some HIV drugs will be prescribed in London. Although there are circumstances where the choice of when to use each drug has changed, all drugs will still be available for different situations.
Initially the changes mostly affect the choice of treatment for people who are starting treatment. Most people who are currently on stable treatment will not be asked to change treatment. However, some people on stable treatment will be asked to switch one or more of their current drugs.
The main changes are:
This policy for broadly influencing prescription practice has been part of London drug commissioning for many years.
The details of these changes are explained below.
Cost is the principal reason behind the changes. Widespread cuts across the NHS include nearly all services. HIV is no different to any other service in this respect. Prescribing the most cost effective treatment first will help protect other aspects of HIV services. HIV treatment is also very individual. Treatment will continue to be individualised for each person's circumstances.
Outline of 2011 Process
This year the Consortium changed the process of purchasing drugs. This required drug manufacturing companies to tender bids for the costs of their drugs for a range of clinical settings, for example for first-line therapy or for first treatment failure etc. This process has taken several months. It has involved input from doctors from the leading HIV hospitals, pharmacists and community advocates.
The tender included the option for a sliding scale of costs if larger quantities are used.
The principles for this process are important:
All manufacturers had the opportunity to modify aspects of their bids to standardise them with other aspects of the tender process, especially in relation to the staggered price related to the volume of drugs purchased.
These budget estimates are dependent on reaching projected target volumes for each drug, including maintaining current drugs levels for some existing drugs. In order to reach or maintain these targets over the year, every London clinic will be working to the same guidelines. Although a clinic can prescribed outside these guidelines the drug costs for those patients will not be reimbursed by the London HIV Consortium.
HIV care is faced with the challenge of being managed and maintained under the financial constraints being imposed on the NHS. This has to be done without jeopardising patient care and these guidelines have the potential to improve patient care in many cases.
An audit will track the outcomes from key treatment changes, initially at three-monthly intervals, to confirm that safety and efficacy is maintained.
These recommendations broadly fall within the BHIVA guidelines (though these have not been significantly revised since 2008), which include the importance of cost effectiveness when clinical data support several therapeutic choices.
HIV care remains one of the most cost-effective medical interventions. These proposed changes minimise disruptions to patient care, maintain access to high quality drugs and retain flexibility for individualised care.
Although this tender is for two years the clinical guidelines will be reviewed and changed if new research raises concerns about the clinical use of any of the preferred drugs.
What This Means in Practice
The recommendations for people starting treatment and people already on treatment and are summarised below.
1. Treatment-Naive Patients
When there are clinical reasons not to use any of these drugs, alternatives can of course be used. This includes drug resistance, concern for side effects, shift work, pregnancy, high viral load (over 100,000 for abacavir) or high risk of heart disease (a greater than 10% risk over ten years, again for abacavir). If abacavir/3TC is not appropriate tenofovir/FTC is recommended.
a) Atazanavir/r is recommended as the first choice if efavirenz or nevirapine are not appropriate.
b) Tenofovir/FTC is recommended when abacavir/3TC is not appropriate.
c) Other drugs can be used when there is a clinical need. For example, alternative protease inhibitors can be used whenever these are clinically more appropriate.
This main change for people starting treatment is that there will be more people using two pills a day rather than one. First-line treatment will still use once-daily combinations and number of daily doses is probably more important than daily pill count. All the recommended combinations are already widely used.
In practice this should not be a significant problem for most people. Most people prefer one drug to two, but there are few studies that show it makes a difference to adherence or to clinical results. While the ease of use of single-pill formulations are popular, there are little data suggesting that one vs two pills daily has a poorer clinical outcome.
When there are clinical reasons to use alternatives, these will still be used. Common reasons not to use abacavir/3TC includes a higher risk of heart disease and a viral load >100,000 copies/mL when starting treatment (based on ACTG 5202). For a few people this might also include higher lipids as tenofovir/FTC has a better lipid profile than abacavir/3TC.
Atazanavir/r is already a widely used, once-daily protease inhibitor that is generally easy to tolerate and easy to modify in case of side effects. This has the potential to improve combinations, for example for people currently taking twice-daily protease inhibitors. Switching to alternatives, including back to the original treatment is possible at all stages if this is needed.
The commissioners already influence drug prescribing. Currently there are financial incentives for clinics to start at least 85% of new patients on NNRTI-based combinations using CQUINs (DoH Commissioning for Quality and Innovations). For 2011/12 clinics that do not broadly follow the new guidelines, threatening to derail the pan-London approach, will having their drug budget witheld entirely.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)